Whittier Trust Co. of Nevada Inc. Lowers Holdings in West Pharmaceutical Services, Inc. $WST

Whittier Trust Co. of Nevada Inc. reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 57.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,009 shares of the medical instruments supplier’s stock after selling 13,632 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in West Pharmaceutical Services were worth $2,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Darwin Wealth Management LLC boosted its position in shares of West Pharmaceutical Services by 10.8% during the fourth quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 40 shares during the last quarter. IFM Investors Pty Ltd increased its holdings in West Pharmaceutical Services by 0.3% in the 1st quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 43 shares during the last quarter. Aptus Capital Advisors LLC increased its holdings in West Pharmaceutical Services by 5.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after acquiring an additional 47 shares during the last quarter. Faithward Advisors LLC lifted its stake in West Pharmaceutical Services by 0.4% in the 3rd quarter. Faithward Advisors LLC now owns 11,855 shares of the medical instruments supplier’s stock worth $3,110,000 after purchasing an additional 48 shares in the last quarter. Finally, PFG Advisors lifted its stake in West Pharmaceutical Services by 1.5% in the 3rd quarter. PFG Advisors now owns 3,302 shares of the medical instruments supplier’s stock worth $866,000 after purchasing an additional 50 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Chad Winters sold 896 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This trade represents a 14.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on WST. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. KeyCorp increased their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday. Stephens reaffirmed an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Wolfe Research initiated coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $351.91.

West Pharmaceutical Services Trading Down 1.5%

Shares of NYSE:WST traded down $5.36 during trading on Tuesday, hitting $352.28. The company had a trading volume of 103,782 shares, compared to its average volume of 914,981. The stock has a market cap of $24.89 billion, a price-to-earnings ratio of 47.10, a price-to-earnings-growth ratio of 3.06 and a beta of 1.16. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The company has a fifty day simple moving average of $323.60 and a two-hundred day simple moving average of $279.56. West Pharmaceutical Services, Inc. has a one year low of $206.80 and a one year high of $367.66.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. The firm had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.